Total Payments
$1,026
2024 Payments
$32.40
Companies
14
Transactions
56
Medicare Patients
1,027
Medicare Billing
$324,571
Payment Breakdown by Category
Food & Beverage$1,026 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,026 | 56 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $337.48 | 25 | $0 (2024) |
| Indivior Inc. | $138.81 | 2 | $0 (2021) |
| Allergan, Inc. | $112.49 | 7 | $0 (2020) |
| ITI, Inc. | $79.48 | 4 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $65.97 | 3 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $58.68 | 3 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $48.04 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.01 | 3 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $32.78 | 2 | $0 (2021) |
| Axsome Therapeutics, Inc. | $26.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.40 | 2 | ABBVIE INC. ($32.40) |
| 2023 | $177.29 | 8 | ABBVIE INC. ($78.37) |
| 2022 | $133.85 | 7 | ABBVIE INC. ($44.50) |
| 2021 | $295.96 | 22 | AbbVie Inc. ($182.21) |
| 2020 | $82.68 | 5 | Allergan, Inc. ($31.21) |
| 2019 | $120.30 | 7 | Allergan Inc. ($35.99) |
| 2018 | $168.07 | 4 | Indivior Inc. ($125.14) |
| 2017 | $15.17 | 1 | Allergan Inc. ($15.17) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: NEUROSCIENCE | ||||||
| 01/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: PSYCHIATRY | ||||||
| 07/19/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Psychology/Psychiatric | ||||||
| 07/10/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.91 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: NEUROSCIENCE | ||||||
| 03/16/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.73 | General |
| Category: Neuropsychiatry | ||||||
| 03/02/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: PSYCHIATRY | ||||||
| 10/07/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: CNS | ||||||
| 09/21/2022 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2022 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Neuroscience | ||||||
| 08/03/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Neuropsychiatry | ||||||
| 03/24/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: NEUROSCIENCE | ||||||
| 01/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA, INVEGA | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Neuroscience | ||||||
| 12/16/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.03 | General |
| Category: NEUROSCIENCE | ||||||
| 11/30/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.17 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.95 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: NEUROSCIENCE | ||||||
| 09/07/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 240 | 1,780 | $327,120 | $129,085 |
| 2022 | 3 | 250 | 649 | $122,444 | $49,032 |
| 2021 | 3 | 197 | 828 | $156,792 | $65,955 |
| 2020 | 5 | 340 | 1,235 | $172,310 | $80,499 |
Total Patients
1,027
Total Services
4,492
Medicare Billing
$324,571
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 863 | $188,445 | $79,834 | 42.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 109 | 890 | $129,691 | $46,008 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $8,985 | $3,243 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 291 | $63,543 | $27,355 | 43.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 112 | 322 | $46,922 | $17,427 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $11,979 | $4,250 | 35.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 64 | 361 | $78,828 | $36,254 | 46.0% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 80 | 414 | $60,328 | $23,031 | 38.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 53 | 53 | $17,636 | $6,670 | 37.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 127 | 567 | $91,339 | $42,765 | 46.8% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 134 | 586 | $63,401 | $31,027 | 48.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 51 | 51 | $16,021 | $5,910 | 36.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 15 | 16 | $800.00 | $630.40 | 78.8% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 13 | 15 | $750.00 | $167.67 | 22.4% |
About Dr. Asad Khan, MD
Dr. Asad Khan, MD is a Forensic Psychiatry healthcare provider based in South Daytona, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1629200647.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Asad Khan, MD has received a total of $1,026 in payments from pharmaceutical and medical device companies, with $32.40 received in 2024. These payments were reported across 56 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($1,026).
As a Medicare-enrolled provider, Khan has provided services to 1,027 Medicare beneficiaries, totaling 4,492 services with total Medicare billing of $324,571. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Forensic Psychiatry
- Other Specialties Psychiatry, Psychiatry
- Location South Daytona, FL
- Active Since 08/10/2009
- Last Updated 08/25/2014
- Taxonomy Code 2084F0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629200647
Products in Payments
- VRAYLAR (Drug) $415.17
- SUBLOCADE (Drug) $138.81
- CAPLYTA (Drug) $79.48
- INGREZZA (Drug) $48.04
- REXULTI (Drug) $42.93
- INVEGA SUSTENNA (Drug) $34.45
- LATUDA (Drug) $32.78
- Auvelity (Drug) $26.99
- Trintellix (Drug) $26.01
- SPRAVATO (Drug) $24.23
- ARISTADA (Drug) $23.77
- NUPLAZID (Drug) $23.66
- ABILIFY MAINTENA (Drug) $23.04
- NUEDEXTA (Drug) $19.96
- BYSTOLIC (Drug) $19.63
- TRINTELLIX (Drug) $17.00
- VIIBRYD (Drug) $15.17
- NEUROSTAR TMS THERAPY (Device) $14.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.